Analogue: Phenotropil

Expiration date: 01/2025

Composition

1 tablet contains:

active substance: phenylpiracetam – 50mg or 100mg;

excipients: povidone K-17, microcrystalline cellulose, sodium carboxy-methyl starch, magnesium stearate.

Pharmacodynamics

A nootropic drug that has a pronounced antiamnestic effect, promotes memory consolidation, facilitates the learning process, increases the resistance of brain tissues to toxic effects, and has an anticonvulsant effect.

It has a positive effect on metabolic processes, stimulates redox processes, increases the energy potential of the body due to the utilization of glucose. Increases the content of norepinephrine, dopamine and serotonin in the brain, does not affect the level of GABA, does not bind to GABA and GABA receptors, does not have a noticeable effect on the spontaneous bioelectric activity of the brain.

It does not affect respiration and the cardiovascular system, shows an unexpressed diuretic effect, has anorexigenic activity when used for a course.

The stimulating effect is manifested in the ability to have a moderate effect, manifested in relation to motor reactions, increasing physical performance, as well as reducing the severity of the hypnotic effect of ethanol and hexobarbital.

Psychostimulating action prevails in the ideative sphere.

Adaptogenic effect is manifested in increasing the body's resistance to stress in conditions of excessive mental and physical exertion, fatigue, hypokinesia and immobilization, at low temperatures.

Against the background of taking the drug, there was an improvement in vision, which is manifested in an increase in acuity, brightness and visual fields.

Improves blood supply to the lower extremities.

Stimulates the production of antibodies in response to antigens, indicating immunostimulatory properties, but at the same time contributes to the development of hypercast-vitalnosti of immediate type and does not alter the allergic inflammatory reaction of the skin caused by the introduction of foreign protein.

With course use, drug dependence, tolerance, and "withdrawal syndrome"do not develop.

The effect is manifested at a single dose, which is important when using the drug in extreme conditions.

Pharmacokinetics

Absorption

Quickly absorbed. Absolute bioavailability with oral administration is 100 %.

Distribution

Penetrates into various organs and tissues, easily passes through the blood-brain barrier. The maximum concentration in the blood (Tmax) is reached after 1 hour.

Metabolism

It is not metabolized in the body.

Breeding

Half-life (T1 / 2) - 3-5 hours.It is excreted unchanged: approximately 40 % - by the kidneys and 60 % - with bile and sweat.

Indications for use

• Diseases of the Central nervous system of various origins, accompanied by deterioration of intellectual and mnestic functions, reduced motor activity.
• The neurotic condition manifested by memory loss.
• Violations of the learning process.
• Psycho-organic syndromes that manifest intellectual and mnestic disorders.
• Convulsive States.
• Obesity (alimentary-constitutional origin).
• Prevention of hypoxia, increasing resistance to stress, correction of the functional state of the body in extreme conditions of professional activity in order to prevent the development of fatigue and to improve mental and physical performance.
• Chronic alcoholism (in order to reduce intellectual and mnestic disorders).

Contraindications

Hypersensitivity to phenylpiracetam or any excipient in the drug.

Pregnancy and breast-feeding.

Age up to 18 years (due to the lack of clinical data on the effectiveness and safety of the use of phenylpiracetam in this age population).

With caution

In patients with severe organic lesions of the liver and kidneys, severe arterial hypertension, with severe atherosclerosis, who have previously suffered panic attacks, acute psychotic States that occur with psychomotor agitation-due to the possibility of exacerbation of anxiety, panic, hallucinations and delusions, as well as in patients with allergic reactions to nootropic drugs of the pyrrolidone group.

Use during pregnancy and breastfeeding

There are no data on randomized clinical trials of phenylpiracetam in pregnant women, therefore, the use of the drug Nanotropil ® Novo during pregnancy and breastfeeding is contraindicated.

Dosage and administration

Inside.

Take immediately after meals. The dose and duration of treatment should be determined by the doctor. Doses vary depending on the characteristics of the patient's condition. The average single dose is 150 mg (100 to 250 mg); the average daily dose is 250 mg (200 to 300 mg). The maximum daily dose of Nanotropil ® Novo is 750 mg. It is recommended to take a daily dose of up to 100 mg once in the morning, and over 100 mg divided into 2 doses. The duration of treatment can vary from 2 weeks to 3 months, with an average of 30 days. If necessary, the course can be repeated in 1 month.

To improve performance-100-200 mg once in the morning, for 2 weeks (for athletes – 3 days).

The recommended duration of therapy with the drug in patients with alimentary-constitutional obesity is 30-60 days at a dose of 100-200 mg once a day (in the morning). It is not recommended to take the drug later than 15 hours.

Side effect

Insomnia (if the drug is taken later than 15 hours). In some patients, in the first 1-3 days of administration, psychomotor agitation, hyperemia of the skin, a feeling of heat, and increased blood pressure are possible.

Overdose

There were no cases of overdose.

Treatment: symptomatic therapy.

Interaction with other drugs

Phenylpiracetam can increase the effects of drugs that stimulate the Central nervous system, and nootropic drugs.

Phenylpiracetam shows a pronounced antagonism to the cataleptic action of neuroleptics,and also weakens the severity of the hypnotic action of ethanol and hexobarbital.

Special instruction

With excessive psychoemotional exhaustion on the background of stress and fatigue, chronic insomnia, a single dose of the drug in the first day can cause a sharp need for sleep. Such patients in outpatient settings should be advised to start the course of taking the drug on non-working days.

Influence on the ability to drive vehicles, mechanisms

Care should be taken when driving vehicles and vehicles, especially in the first days of reception, taking into account the possible occurrence of sleepiness (see "Special instructions").

Form release

Tablets, 50mg, 100mg.

10 tablets in a contour cell package made of polyvinyl chloride film and aluminum printed lacquered foil.

1, 2, 3, 4 or 5 contour cell packages together with instructions for use in a pack of cardboard.

Storage conditions

In a place protected from light at a temperature no higher than 30 °C.

Keep out of reach of children.

Expiration date

3 years. Do not use after the expiration date indicated on the package.